Investors / filer profile

Akkaraju Srinivas

active in 5 companies

Pro
Bought: Pro
Sold: 41
Filings: 5
Companies: 2026-09-08
Last filed

EDGAR · CIK 0001253170 ↗

2 of 4 beat the S&P 500

median +13.7% · S&P 500 +9.7%

4 measured · 1 still running

Money flow · By month

Pro: the money-flow chart and the full record→

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

All filings on record

Every Form 4 transaction we track for this filer


ALMSALUMIS INC.	Bought $2.90M · 273,290 sh	2026-09-08	—
ALMSALUMIS INC.	Bought $2.90M · 273,291 sh	2026-09-08	—
ALMSALUMIS INC.	Sold $507.0K · 48,065 sh	2026-09-08	—
ALMSALUMIS INC.	Sold $507.0K · 48,066 sh	2026-09-08	—
ALMSALUMIS INC.	Bought $2.46M · 220,070 sh	2026-09-04	—
ALMSALUMIS INC.	Bought $2.46M · 220,070 sh	2026-09-04	—
ALMSALUMIS INC.	Grant — · 3,553 sh	2026-06-30	—
KLRSKalaris Therapeutics, Inc.	Other — · 4,471 sh	2026-05-20	—
KLRSKalaris Therapeutics, Inc.	Other — · 14,937 sh	2026-05-20	—
KLRSKalaris Therapeutics, Inc.	Other — · 66,906 sh	2026-05-20	—

ALMSBought

2026-09-08 · ALUMIS INC.

$2.90M

—

ALMSBought

2026-09-08 · ALUMIS INC.

$2.90M

—

ALMSSold

2026-09-08 · ALUMIS INC.

$507.0K

—

ALMSSold

2026-09-08 · ALUMIS INC.

$507.0K

—

ALMSBought

2026-09-04 · ALUMIS INC.

$2.46M

—

ALMSBought

2026-09-04 · ALUMIS INC.

$2.46M

—

ALMSGrant

2026-06-30 · ALUMIS INC.

3,553

—

KLRSOther

2026-05-20 · Kalaris Therapeutics, Inc.

4,471

—

KLRSOther

2026-05-20 · Kalaris Therapeutics, Inc.

14,937

—

KLRSOther

2026-05-20 · Kalaris Therapeutics, Inc.

66,906

—

Newest 10 of 41 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.